Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

What to Do When Patch Testing is Negative?

American Contact Dermatitis Society (ACDS)

M. Montanez-Wiscovich

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Incyte

C. Harrison

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

BMFcases

T. Bat, A. Tefferi

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

When to Switch From Hydroxyurea to Ruxolitinib in PV

Prithviraj Bose

2024 Updates in Myeloproliferative Neoplasms

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Hexner

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

CYTO-PV Study: Importance of Hematocrit Control and Early Interventi…

Monia Marchetti

Importance of Early Management of Patients with Myelofibrosis (MF)

Incyte

P. Bose, R. Rampal

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin